Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Comparative proteomic analysis of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma

  • 1,
  • 2,
  • 1,
  • 3,
  • 2,
  • 1,
  • 4 and
  • 1Email author
Retrovirology20118(Suppl 1):A9

https://doi.org/10.1186/1742-4690-8-S1-A9

Published: 6 June 2011

Keywords

  • Lymphoma
  • Membrane Protein
  • Cancer Stem Cell
  • Proteomic Analysis
  • Protein Profile

Adult T-cell leukemia (ATL) is a T-cell malignancy caused by HTLV-1. In ATL, chemotherapeutic responses are generally poor, which has suggested the existence of chemotherapy-resistant cancer stem cells (CSCs). The HTLV-I transactivator, Tax, initiates ATL-like disease (mATL) in Tax transgenic mice. Recently, the CSCs of mATL were identified. The CSCs in a side population, could consistently regenerate the original lymphoma and overlapped with a minor population of CD38(-)/CD71(-)/CD117(+) cells, suggesting that the eradication of cancer stem cells will be necessary to improve the outcome of treatment for mATL. In designing specific regimens for CSCs, antibody-based therapy appears to be a promising way to destroy CSCs. A small number of target antigens on cancer stem cells have been described. It remains to be determined, however, whether these and other targets will distinguish cancer stem cells from normal tissues.

In this study, a proteomic approach was used to identify proteins differentially expressed in CSCs of mATL. The CSCs of mATL were isolated using cell sorting, and analyzed by label-free LC-MS/MS to compare protein profiles in CSCs and no-CSCs. More than 700 proteins were detected. The levels of 53 proteins were increased in CSCs. An interesting finding is that these proteins included one membrane protein, which might potentially serve as a new target of antibody-based therapy. Flow cytometry validated expression of the membrane protein. Taken together, the data presented provide a significant new protein-level insight into the biology of cancer stem cells of mATL, a key population which are involved in mATL development.

Authors’ Affiliations

(1)
Department pathology, National Institute of Infectious Diseases, Musashimurayama, Japan
(2)
Advanced Medical Research Center, Yokohama City University, Yokohama, Japan
(3)
Department of Microbiology and Molecular Biodefense Resarch, Yokohama City University, Yokohama, Japan
(4)
Center for Research in Infectious Disease, University College Dublin, Dublin, Ireland

Copyright

© Suzuki et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement